TROP2 methylation and expression in tamoxifen-resistant breast cancer
Stephanie M Zimmers1, Eva P Browne1, Kristin E Williams1
11Department of Veterinary & Animal Sciences, University of Massachusetts, Amherst, Life Sciences Laboratories, Room 540D, 240 Thatcher Road, Amherst, MA 01003 USA.
Background:
The DNA methyltransferase 1 inhibitor, 5-Aza-2'-deoxycytidine (5-Aza-dC) is a potential treatment for breast cancer. However, not all breast tumors will respond similarly to treatment with 5-Aza-dC, and little is known regarding the response of hormone-resistant breast cancers to 5-Aza-dC.
Methods:
We demonstrate that 5-Aza-dC-treatment has a stronger effect on an estrogen receptor-negative, Tamoxifen-selected cell line, TMX2-28, than on the estrogen receptor-positive, MCF7, parental cell line. Using data obtained from the HM450 Methylation Bead Chip, pyrosequencing, and RT-qPCR, we identified a panel of genes that are silenced by promoter methylation in TMX2-28 and re-expressed after treatment with 5-Aza-dC.
Results:
One of the genes identified, tumor associated calcium signal transducer 2 (TACSTD2), is altered by DNA methylation, and there is evidence that in some cancers decreased expression may result in greater proliferation. Analysis of DNA methylation of TACSTD2 and protein expression of its product, trophoblast antigen protein 2 (TROP2), was extended to a panel of primary (n = 34) and recurrent (n = 34) breast tumors. Stratifying tumors by both recurrence and ER status showed no significant relationship between TROP2 levels and TACSTD2 methylation. Knocking down TACSTD2 expression in MCF7 increased proliferation however; re-expressing TACSTD2 in TMX2-28 did not inhibit proliferation, indicating that TACSTD2 re-expression alone was insufficient to explain the decreased proliferation observed after treatment with 5-Aza-dC.
Conclusions:
These results illustrate the complexity of the TROP2 signaling network. However, TROP2 may be a valid therapeutic target for some cancers. Further studies are needed to identify biomarkers that indicate how TROP2 signaling affects tumor growth and whether targeting TROP2 would be beneficial to the patient.
Insights
5-Aza-2'deoxycytidine (5-Aza-dC) shows differential effects on breast cancer cells, impacting hormone-resistant and estrogen receptor-negative tumors more significantly. TACSTD2 re-expression alone did not fully explain decreased proliferation, highlighting complex signaling networks.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- 5-Aza-2'-deoxycytidine (5-Aza-dC) is a DNA methyltransferase 1 inhibitor explored for breast cancer treatment.
- Response to 5-Aza-dC varies among breast tumors, particularly in hormone-resistant types.
Purpose of the Study:
- To investigate the differential effects of 5-Aza-dC on estrogen receptor-positive and -negative breast cancer cells.
- To identify genes regulated by DNA methylation and 5-Aza-dC treatment in breast cancer.
Main Methods:
- Comparative analysis of 5-Aza-dC treatment on MCF7 (ER-positive) and TMX2-28 (ER-negative) cell lines.
- Utilized HM450 Methylation Bead Chip, pyrosequencing, and RT-qPCR to identify and validate gene expression changes.
- Assessed DNA methylation and protein expression of TACSTD2/TROP2 in primary and recurrent breast tumors.
Main Results:
- 5-Aza-dC exhibited a stronger effect on the ER-negative TMX2-28 cell line compared to the ER-positive MCF7 cell line.
- Identified TACSTD2 as a gene silenced by methylation in TMX2-28, re-expressed upon 5-Aza-dC treatment.
- No significant correlation found between TROP2 protein levels and TACSTD2 methylation in primary or recurrent tumors; TACSTD2 knockdown increased MCF7 proliferation, but re-expression in TMX2-28 did not inhibit proliferation.
Conclusions:
- The re-expression of TACSTD2 alone does not fully account for the anti-proliferative effects of 5-Aza-dC in TMX2-28 cells.
- The TROP2 signaling network is complex, suggesting TROP2 may be a therapeutic target in specific cancer contexts.
- Further research is required to identify biomarkers for TROP2's role in tumor growth and its therapeutic potential.
Related Concept Videos
Treatment Resistant Cancers
Resistivity
Resistance
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Rolling Resistance
For instance, imagine a hard cylinder rolling on a comparatively soft surface. The cylinder's weight compresses the surface beneath it. As the cylinder moves, the material in front of it slows down due to...


